Side-by-side comparison of the two leading incretin peptides: mechanism, half-life, head-to-head trial data, and how to think about them.
Semaglutide and tirzepatide dominate modern metabolic peptide research. They share an incretin lineage but differ meaningfully — semaglutide targets a single receptor, tirzepatide targets two. The SURPASS-2 trial is the canonical head-to-head reference.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Receptors activated | 1 (GLP-1) | 2 (GIP + GLP-1) |
| Half-life | ~7 days | ~5 days |
| Dosing cadence | Once weekly | Once weekly |
| Average weight reduction (52-wk trials) | ~15% (STEP) | ~20–22% (SURMOUNT-1) |
| FDA-approved brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Common GI tolerability | Comparable nausea profile | Comparable nausea profile |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is one of the most-studied incretin-class molecules and underpins several FDA-approved branded medications in clinical settings.
Semaglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, slowing gastric emptying, and acting on central appetite-regulation pathways.
Tirzepatide is a synthetic peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-incretin profile has drawn significant clinical and research interest.
By engaging GIP and GLP-1 receptors simultaneously, tirzepatide influences insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.
Tirzepatide's dual-receptor profile produces larger average effects in head-to-head clinical trials. Individual response varies, and any clinical decision should be made with a licensed practitioner.
The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, hitting two incretin pathways at once.
Yes. Any clinical use must be directed by a licensed medical practitioner. Research-use product is supplied for investigational purposes only.
Head-to-head clinical trials (SURPASS-2) suggest greater average weight reduction with tirzepatide, but individual response varies and any clinical decision should be made with a licensed provider.
Tirzepatide activates two receptors (GIP and GLP-1) on the same molecule, in contrast to semaglutide which targets only GLP-1.